In this Q&A, Carly Stafford Dixon discusses her lymphoma journey, recovery with CAR T therapy, and mission to raise support ...

Yescarta (axicabtagene ciloleucel) has been approved as a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma ...

The approved indications for Yescarta are adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more ...

Long-term results from a randomized trial confirmed that early rituximab monotherapy for advanced-stage, asymptomatic, low ...

Primary non-Hodgkin's lymphoma of the breast (PBNHL) is uncommon. There have been only a few reports of breast lymphoma in the radiology literature. In this case report, we describe mammographic ...

Apr. 29, 2025 — A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete ...

First-line treatment with a Keytruda combo had an overall survival of 17.6 months in some with recurrent/metastatic head and ...

On the Importance of Individualized, Non-Coplanar Beam Configurations in Mediastinal Lymphoma Radiotherapy, Optimized With Automated Planning. Front Oncol. 2021 Apr 15;11:619929. doi: 10.3389/fonc.

Lacking awareness of metabolic dysfunction-associated steatohepatitis (MASH) constitutes a critical barrier for enhancing patient care, said Naim Alkhouri, MD. Awareness efforts can not only increase ...

STOCKHOLM, May 3, 2025 /PRNewswire/ -- At this week's ESTRO conference in Vienna, RaySearch Laboratories AB (publ) and Vision RT proudly announces the next step in their collaboration: the full ...